First Time Loading...

Heron Therapeutics Inc
NASDAQ:HRTX

Watchlist Manager
Heron Therapeutics Inc Logo
Heron Therapeutics Inc
NASDAQ:HRTX
Watchlist
Price: 2.77 USD -6.42% Market Closed
Updated: May 13, 2024

Intrinsic Value

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. [ Read More ]

The intrinsic value of one HRTX stock under the Base Case scenario is 3.29 USD. Compared to the current market price of 2.77 USD, Heron Therapeutics Inc is Undervalued by 16%.

Key Points:
HRTX Intrinsic Value
Base Case
3.29 USD
Undervaluation 16%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Heron Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling HRTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Heron Therapeutics Inc

Provide an overview of the primary business activities
of Heron Therapeutics Inc.

What unique competitive advantages
does Heron Therapeutics Inc hold over its rivals?

What risks and challenges
does Heron Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Heron Therapeutics Inc recently?

Summarize the latest earnings call
of Heron Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Heron Therapeutics Inc.

Provide P/S
for Heron Therapeutics Inc.

Provide P/E
for Heron Therapeutics Inc.

Provide P/OCF
for Heron Therapeutics Inc.

Provide P/FCFE
for Heron Therapeutics Inc.

Provide P/B
for Heron Therapeutics Inc.

Provide EV/S
for Heron Therapeutics Inc.

Provide EV/GP
for Heron Therapeutics Inc.

Provide EV/EBITDA
for Heron Therapeutics Inc.

Provide EV/EBIT
for Heron Therapeutics Inc.

Provide EV/OCF
for Heron Therapeutics Inc.

Provide EV/FCFF
for Heron Therapeutics Inc.

Provide EV/IC
for Heron Therapeutics Inc.

Show me price targets
for Heron Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Heron Therapeutics Inc?

How accurate were the past Revenue estimates
for Heron Therapeutics Inc?

What are the Net Income projections
for Heron Therapeutics Inc?

How accurate were the past Net Income estimates
for Heron Therapeutics Inc?

What are the EPS projections
for Heron Therapeutics Inc?

How accurate were the past EPS estimates
for Heron Therapeutics Inc?

What are the EBIT projections
for Heron Therapeutics Inc?

How accurate were the past EBIT estimates
for Heron Therapeutics Inc?

Compare the revenue forecasts
for Heron Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Heron Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Heron Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Heron Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Heron Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Heron Therapeutics Inc with its peers.

Analyze the financial leverage
of Heron Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Heron Therapeutics Inc.

Provide ROE
for Heron Therapeutics Inc.

Provide ROA
for Heron Therapeutics Inc.

Provide ROIC
for Heron Therapeutics Inc.

Provide ROCE
for Heron Therapeutics Inc.

Provide Gross Margin
for Heron Therapeutics Inc.

Provide Operating Margin
for Heron Therapeutics Inc.

Provide Net Margin
for Heron Therapeutics Inc.

Provide FCF Margin
for Heron Therapeutics Inc.

Show all solvency ratios
for Heron Therapeutics Inc.

Provide D/E Ratio
for Heron Therapeutics Inc.

Provide D/A Ratio
for Heron Therapeutics Inc.

Provide Interest Coverage Ratio
for Heron Therapeutics Inc.

Provide Altman Z-Score Ratio
for Heron Therapeutics Inc.

Provide Quick Ratio
for Heron Therapeutics Inc.

Provide Current Ratio
for Heron Therapeutics Inc.

Provide Cash Ratio
for Heron Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Heron Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Heron Therapeutics Inc?

What is the current Free Cash Flow
of Heron Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Heron Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Heron Therapeutics Inc

Current Assets 188.8m
Cash & Short-Term Investments 80.4m
Receivables 60.1m
Other Current Assets 48.2m
Non-Current Assets 33.7m
PP&E 25.6m
Other Non-Current Assets 8.1m
Current Liabilities 79.7m
Accounts Payable 3.2m
Accrued Liabilities 76.4m
Non-Current Liabilities 176.8m
Long-Term Debt 149.5m
Other Non-Current Liabilities 27.3m
Efficiency

Earnings Waterfall
Heron Therapeutics Inc

Revenue
127m USD
Cost of Revenue
-65.1m USD
Gross Profit
61.9m USD
Operating Expenses
-172.6m USD
Operating Income
-110.6m USD
Other Expenses
56k USD
Net Income
-110.6m USD

Free Cash Flow Analysis
Heron Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

HRTX Profitability Score
Profitability Due Diligence

Heron Therapeutics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

50/100
Profitability
Score

Heron Therapeutics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

HRTX Solvency Score
Solvency Due Diligence

Heron Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
38/100
Solvency
Score

Heron Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HRTX Price Targets Summary
Heron Therapeutics Inc

Wall Street analysts forecast HRTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HRTX is 6.89 USD with a low forecast of 5.05 USD and a high forecast of 9.45 USD.

Lowest
Price Target
5.05 USD
82% Upside
Average
Price Target
6.89 USD
149% Upside
Highest
Price Target
9.45 USD
241% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

HRTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

HRTX Price
Heron Therapeutics Inc

1M 1M
-6%
6M 6M
+408%
1Y 1Y
+108%
3Y 3Y
-82%
5Y 5Y
-84%
10Y 10Y
-76%
Annual Price Range
2.77
52w Low
0.54
52w High
3.06
Price Metrics
Average Annual Return -26.43%
Standard Deviation of Annual Returns 47.56%
Max Drawdown -98%
Shares Statistics
Market Capitalization 416.3m USD
Shares Outstanding 150 285 000
Percentage of Shares Shorted 19.48%

HRTX Return Decomposition
Main factors of price return

What is price return decomposition?

HRTX News

Other Videos

Company Profile

Heron Therapeutics Inc Logo
Heron Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

416.3m USD

Dividend Yield

0%

Description

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in San Diego, California and currently employs 302 full-time employees. The firm commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.

Contact

CALIFORNIA
San Diego
4242 Campus Point Ct Ste 200
+18582514400.0
http://www.herontx.com/

IPO

1987-08-26

Employees

302

Officers

CEO & Director
Mr. Craig Alexander Collard
Executive VP & CFO
Ms. Ira Duarte
Chief Scientific Officer and Senior VP of Pharmaceutical & Translational Sciences
Dr. Thomas B. Ottoboni Ph.D.
Vice President of Marketing
Mr. Ryan Craig
Senior Vice President of Human Resources
Mr. Sean T. Ristine
Senior VP of Oncology Care Franchise & Commercial Operations
Mr. Robert Sullivan
Show More
Executive VP & Chief Development Officer
Dr. William P. Forbes Pharm. D., Pharm.D.
Executive Director, Assistant General Counsel & Assistant Secretary
Jeff Cohn
Show Less

See Also

Discover More
What is the Intrinsic Value of one HRTX stock?

The intrinsic value of one HRTX stock under the Base Case scenario is 3.29 USD.

Is HRTX stock undervalued or overvalued?

Compared to the current market price of 2.77 USD, Heron Therapeutics Inc is Undervalued by 16%.